COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.

Brodard, Justine; Kremer Hovinga, Johanna A.; Fontana, Pierre; Studt, Jan-Dirk; Gruel, Yves; Greinacher, Andreas (2021). COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. Journal of thrombosis and haemostasis, 19(5), pp. 1294-1298. Wiley-Blackwell 10.1111/jth.15262

[img] Text
COVID-19_patients_.pdf - Accepted Version
Restricted to registered users only until 8 February 2022.
Available under License Publisher holds Copyright.

Download (6MB) | Request a copy

BACKGROUND

Heparin-induced thrombocytopenia (HIT) is a severe adverse reaction to heparin caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin is a cornerstone of treatment in critically ill COVID-19 patients. HIT antibodies can be detected by antigen tests and functional tests. Often strong reactivity in the antigen test is used as surrogate marker for the presence of clinically relevant, platelet activating antibodies. We observed an unexpectedly high percentage of COVID-19 patients, clinically suspected to have HIT, with high titer anti-PF4/heparin antibodies, but a negative functional test.

OBJECTIVE

We investigated whether in COVID-19 patients a serum-derived factor inhibits the heparin-induced platelet activation test (HIPA).

METHODS AND RESULTS

12 COVID-19 patients with suspected HIT were tested. Three samples tested negative in all assays; nine samples tested positive by antigen tests, among which only three tested also positive by HIPA. When we spiked COVID-19 serum or control serum with the human HIT antibody like mAb 5B9, reactivity of 5B9 remained the same. Also the purified IgG fractions of COVID-19 sera testing strongly positive in the PF4/heparin antigen test but negative in the functional test did not show increased reactivity in the functional test in comparison to the original serum. Both results make a functionally inhibitory factor in the serum/plasma of COVID-19 patients highly unlikely.

CONCLUSION

COVID-19 patients often present with strong reactivity in PF4/heparin antigen tests without the presence of platelet-activating antibodies. Diagnosis of HIT requires confirmation of heparin-dependent, platelets activating antibodies to avoid overdiagnosis and overtreatment with non-heparin anticoagulants.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Brodard, Justine and Kremer Hovinga, Johanna Anna

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1538-7836

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

18 Feb 2021 08:21

Last Modified:

23 Apr 2021 01:33

Publisher DOI:

10.1111/jth.15262

PubMed ID:

33550713

Uncontrolled Keywords:

COVID-19 Heparin Platelet Factor 4 Thrombocytopenia Thrombosis

BORIS DOI:

10.48350/152391

URI:

https://boris.unibe.ch/id/eprint/152391

Actions (login required)

Edit item Edit item
Provide Feedback